Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome

Not Applicable

Completed

• Conditions: Acute Myocardial Infarction; Angina Pectoris
• Interventions: Device: iFR; Device: FFR

• Registration Number: NCT02166736
• Lead Sponsor: Uppsala University

Brief Summary

Previous trials have demonstrated that the use of physiological assessment of stenosis severity using fractional flow reserve (FFR) is superior to angiographic assessment in percutaneous coronary intervention (PCI) and improves clinical outcome. Despite the clinical utility, FFR is used only in 10-15% of patients today. The main reasons for the low adoption rate of FFR are the prolonged procedural time, Adenosine related discomfort and cost associated with Adenosine.

Instantaneous Wave-Free ratio (iFR®) is a novel method to assess coronary lesions for functional significance. The main benefits of the method compared to FFR are that the measurement is instantaneous and does not require Adenosine infusion. Thus, the patient does not experience any discomfort from the measurement and procedural time could be shortened compared to when using FFR. This could potentially increase the adoption rate of physiologic assessment of coronary lesions.

The aim of this trial is to compare the clinical outcome of patients assessed by iFR® with patients assessed by FFR.

Furthermore, the trial will be conducted as a registry based randomized clinical trial (RRCT) which is a novel strategy to conduct clinical trials. The randomization will occur online in the Swedish angiography and angioplasty registry (SWEDEHEART) using a web based platform.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-05-07
• Study First Submitted QC: 2014-06-14
• Study First Posted: 2014-06-18
• Primary Completion: 2015-10
• Study Completion: 2016-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-11
• Last Update Posted: 2017-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2037

Inclusion Criteria

• Patients with suspected stable angina pectoris or unstable angina pectoris/non-ST-segment elevation myocardial infarction (NSTEMI) who are scheduled to undergo coronary angiography, and who has an indication for physiology guided assessment of coronary lesions (usually 30-80% stenosis grade). In patients with suspected stable angina pectoris, any lesion may be assessed. In patients with unstable angina pectoris/NSTEMI, only the non-culprit lesion may be assessed.

Exclusion Criteria

• Inability to provide informed consent
• Age below 18 years
• Previous randomization in the iFR-SWEDEHEART trial
• Known terminal disease with a life expectancy of less than one year.
• In patients with multi-vessel disease and other indication than stable angina pectoris, difficulty in assessing which the culprit lesion is.
• Patient with unstable hemodynamics (Killip class III-IV)
• Inability to tolerate Adenosine
• Previous Coronary artery bypass graft (CABG) with patent grafts to the interrogated vessel.
• Heavily calcified or tortuous vessel where inability to cross the lesion with a pressure wire is expected.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Instantaneous wave-free ratio (iFR)	iFR	-
Fractional Flow Reserve (FFR)	FFR	-

Primary Outcome Measures

Name	Time	Method
All cause death, non-fatal Myocardial infarction (MI), Unplanned revascularization	12 months

Secondary Outcome Measures

Name	Time	Method
Non-fatal MI	1-5 years
All cause death	1-5 years
Unplanned revascularization	1-5 years
Target lesion revascularization	1-5 years
Time to acute coronary occlusion, stent thrombosis and restenosis in treated lesions as reported in Swedish Coronary Angiography and Angioplasty Registry (SCAAR)	1-5 years
Change in physician´s treatment strategy depending on iFR/FFR information	Day 1	Before randomization, the operators will have to record their angiographic assessment of the coronary lesions and the theoretical treatment strategy based on the angiographic information alone. After randomization and functional assessment of lesion severity, the operators will record how iFR/FFR changed the treatment strategy.
Assessment of patient discomfort during the procedure (none/mild/moderate/severe	Day 1
Procedural time	Day 1

Trial Locations

Locations (14)

Sahlgrenska University Hospital; 🇸🇪 Göteborg, Sweden

Helsingborg County Hospital; 🇸🇪 Helsingborg, Sweden

Halmstad sjukhus; 🇸🇪 Halmstad, Sweden

Kalmar County Hospital; 🇸🇪 Kalmar, Sweden

Karlstad County Hospital; 🇸🇪 Karlstad, Sweden

Linköping University Hospital; 🇸🇪 Linköping, Sweden

Skane University Hospital; 🇸🇪 Lund, Sweden

S:t Göran County Hospital; 🇸🇪 Stockholm, Sweden

Sundsvall County Hospital; 🇸🇪 Sundsvall, Sweden

Västerås County Hospital; 🇸🇪 Västerås, Sweden

Uppsala University Hospital; 🇸🇪 Uppsala, Sweden

Örebro University Hospital; 🇸🇪 Örebro, Sweden

Reykjavik University Hospital; 🇮🇸 Reykjavik, Iceland

Skejby University Hospital; 🇩🇰 Aarhus, Denmark